X

Stay Connected

Sign Up for Updates

We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

Biopharmaceutical industry policies aim to increase access to clinical trial data

By Olivia Shopshear  |    July 27, 2017
Today, a study published in the British Medical Journal (BMJ) sought to audit industry clinical trial disclosure and data sharing policies. The study, entitled Pharmaceutical companies’ policies...   Read More

Opportunities to build upon enhanced competition for medicines in the marketplace

By David Korn  |    July 27, 2017
Last week, I presented at the U.S Food and Drug Administration’s (FDA) public meeting on the Hatch-Waxman Amendments to discuss the balance between encouraging innovation in biopharmaceutical...   Read More

Finding cures for incurable diseases

By Guest Contributor  |    July 25, 2017
By Sandra Raymond, president and CEO, The Lupus Foundation of America   Read More

Medicare Monday: How Part B has evolved over the years

By Nicole Longo  |    July 24, 2017
With Medicare’s birthday rapidly approaching (July 30!), today we’re highlighting a few of the ways reimbursement for physician-administered medicines under Part B has changed since it was first...   Read More

Policy conditions make or break leaders in biopharmaceutical innovation: Preliminary results from the 2017 BCI Survey

By Meir Pugatch  |    July 24, 2017
In a world of global investment flows, securing a larger portion of the $150 billion invested per year by the research-based biopharmaceutical industry is anyone’s game. The 2017 results of the...   Read More

New PhRMA resources chock full of biopharma industry facts

By John Corea  |    July 20, 2017
Did you know that PhRMA member companies invested $65.5 billion in research and development (R&D) in 2016? Or that combined spending on brand medicines, generics and the supply chain account for...   Read More

New video: Patient and researcher fight JRA together

By Amber Lyons  |    July 19, 2017
Have you ever heard of juvenile rheumatoid arthritis (JRA)? A lot of people haven’t.   Read More

New report portrays flourishing pipeline

By Gretta Stone  |    July 18, 2017
It’s an exciting time to be working in the biopharmaceutical industry. Almost every day new headlines highlight remarkable new advances in the fight against disease. Some have called this the...   Read More

Medicare Monday: What you need to know about the latest Medicare Trustees report

By Nicole Longo  |    July 17, 2017
Last week, the Trustees of the Social Security and Medicare trust funds released its annual report on the current and projected financial status of Medicare. Here are a few important takeaways in...   Read More

340B Spotlight: New analysis finds 340B program growth continues to accelerate despite false claims

By Nicole Longo  |    July 13, 2017
This week, Berkeley Research Group (BRG) released a new whitepaper pushing back on the highly misleading claim that 340B sales are only 2 percent of annual U.S. drug sales. Citing a number of...   Read More

Search the Catalyst

View Posts by Topic

see all

Subscribe to Email Updates